Impact of Postoperative Radiotherapy on the Prognosis of Early-Stage (pT1-2N0M0) Oral Tongue Squamous Cell Carcinoma Adults with FLT3-ITD AML in first remission underwent HCT and were randomly ...

Measurement of minimal residual disease (MRD) following treatment of blood cancers is recognized as an important tool for disease management, and MRD negativity is increasingly a benchmark in clinical ...

VANFLYTA also is approved in Japan for the treatment of AML that is FLT3-ITD mutation positive, including for use in combination with standard cytarabine and anthracycline induction and standard ...

SAN DIEGO -- Measurable residual disease (MRD) after induction therapy can guide the use of allogeneic transplant in patients with NPM1-mutated acute myeloid leukemia (AML) in first remission, ...

Data from Phase 3 MORPHO trial selected for press briefing and to be presented as oral session during the 2023 European Hematology Association (EHA) Hybrid Congress Exploratory results demonstrated ...

Invivoscribe® Technologies Inc., a global company with more than 20 years of experience providing clonality and biomarker test solutions for the fields of oncology, personalized molecular diagnostics® ...

This model illustrates how SETD1B promotes the expansion of H3K4me3 epigenetic marks and upregulates MYC expression, driving cytokine-independent cell growth in FLT3-mutated AML. Acute myeloid ...

TORONTO, June 16, 2025 /CNW/ - Daiichi Sankyo's (TSE: 4568) VANFLYTA (quizartinib) has been approved by Health Canada for use in combination with standard cytarabine and anthracycline induction and ...

Biomea Fusion (BMEA) announced preliminary data from the ongoing Phase I COVALENT-103 study evaluating BMF-500, the company’s investigational covalent FLT3 inhibitor developed using the proprietary ...

“In previous research, we showed that patients treated with quizartinib had improved survival compared with patients who didn’t receive the drug. This study further demonstrated that patients treated ...